SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending amidst reports it's considering an all-cash offer for Warner Bros. Discovery, a development seen by many as a bullish move to solidify the deal and avoid shareholder dilution, despite fierce competition from another suitor. The community is actively debating how this acquisition, alongside catalysts like expanding ad-supported tiers and live content, positions Netflix ahead of its critical earnings release. While many anticipate strong performance from these initiatives, others express caution regarding potential debt and regulatory hurdles.

Webull Corp. engages in the provision of financial services. It offers trading, wealth management product distribution, market data and information, user community, and investor education. The company was founded by An Quan Wang in 2016 and is headquartered in St. Petersburg, FL.

Webull Corp. - Ordinary Shares - Class A

Webull Corp

Webull (BULL) is sparking intense debate as a Zacks Strong Buy rating and reports of robust customer asset growth are met with frustration over persistent dilution and the stock's failure to mirror broader market and crypto gains. Bulls emphasize underlying strong fundamentals and international expansion, seeing a significant valuation opportunity, while bears are vocal about continuous selling pressure and intense competition within the digital brokerage sector.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is commanding significant attention as investors await key Producer Price Index data and a pivotal Supreme Court ruling on tariffs, fueling widespread debate over market direction. Community discussions highlight recurring "V-shaped" recoveries and volatility, with broader concerns about geopolitical events and central bank independence influencing sentiment in this tech-heavy index.

Alpha Tau Medical Ltd. is a clinical-stage oncology therapeutics company, which focuses on the research, development, and commercialization of diffusing alpha-emitters radiation therapy for the treatment of cancer. The firm is involved in the clinical trials at cancer centers with indications that include skin cancer, oral cavity cancer, breast cancer, and pancreatic cancer. The company was founded by Uzi Sofer, Yona Keisari, and Itzhak Kelson in November 2015 and is headquartered in Jerusalem, Israel.

Alpha Tau Medical Ltd

ALPHA TAU MEDICAL LTD

Alpha Tau Medical is experiencing significant buzz driven by a potent combination of catalysts, including highly anticipated Japanese regulatory approval, compelling pancreatic cancer data, and its presentation at the J.P. Morgan Healthcare Conference. The community is actively highlighting this stacking of positive developments, anticipating increased institutional attention and potential index inclusions as the company's innovative alpha-radiation therapy gains wider recognition.

Bank of America Corp. is a bank and financial holding company, which engages in the provision of banking and nonbank financial services. It operates through the following segments: Consumer Banking, Global Wealth and Investment Management (GWIM), Global Banking, Global Markets, and All Other. The Consumer Banking segment offers credit, banking, and investment products and services to consumers and small businesses. The GWIM segment focuses on solutions to meet clients’ needs through a full set of investment management, brokerage, banking, and retirement products. The Global Banking segment deals with lending-related products and services, integrated working capital management and treasury solutions to clients, and underwriting and advisory services. The Global Markets segment includes sales and trading services, as well as research, to institutional clients across fixed-income, credit, currency, commodity, and equity businesses. The All Other segment consists of asset and liability management activities, equity investments, non-core mortgage loans and servicing activities, the net impact of periodic revisions to the mortgage servicing rights valuation model for both core and non-core MSRs, other liquidating businesses, residual expense allocations and other. The company was founded by Amadeo Peter Giannini in 1904 and is headquartered in Charlotte, NC.

Bank Of America Corp.

Bank of America Corp

Bank of America is a major talking point following a strong earnings report driven by robust net interest income, prompting several analyst upgrades and an optimistic outlook from its recent investor day. The community is actively weighing the bank's ambitious return on equity targets against broader financial sector discussions around credit health and its new strategy to recommend crypto allocations to clients.

TG Therapeutics, Inc. engages in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. Its product pipeline includes TG-1501, TG-1701, Ublituximab, and Umbralisib. The company was founded by Michael Sean Weiss and Laurence H. Shaw on May 18, 1993 and is headquartered in Morrisville, NC.

TG Therapeutics Inc

TG Therapeutics is seeing increased attention following strong preliminary Q4 revenue and positive 2026 guidance for its MS treatment, Briumvi, with many anticipating blockbuster status. The community is actively discussing how a recent setback for a competitor's BTK inhibitor further bolsters Briumvi's market position, alongside anticipation for its subcutaneous formulation. Despite positive fundamentals and growth, there's ongoing debate among investors regarding the stock's current valuation and the company's long-term strategy.

Wells Fargo & Co. is a diversified and community-based financial services company, which engages in the provision of banking, insurance, investments, mortgage, and consumer and commercial finance products and services. It operates through the following segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth and Investment Management. The Consumer Banking and Lending segment offers consumer and small business banking, home lending, credit cards, auto, and personal lending. The Commercial Banking segment provides banking and credit products across industry sectors and municipalities, secured lending and lease products, and treasury management. The Corporate and Investment Banking segment is composed of corporate banking, investment banking, treasury management, commercial real estate lending and servicing, and equity and fixed income solutions, as well as sales, trading, and research capabilities. The Wealth and Investment Management segment refers to personalized wealth management, brokerage, financial planning, lending, private banking, trust, and fiduciary products and services. The company was founded by Henry Wells and William G. Fargo on March 18, 1852 and is headquartered in San Francisco, CA.

Wells Fargo & Co.

Wells Fargo is trending after its recent earnings report, where an adjusted EPS beat contrasted with a revenue miss, sparking community focus on its 2026 outlook. Investors are keenly assessing the bank's path to profitable growth and sustained capital returns following the significant removal of its long-standing asset cap.

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

Moderna is experiencing significant upward momentum driven by promising developments across its pipeline, including a combined flu and COVID vaccine and advancements in its oncology partnership with Merck. Investors are responding positively to an improved financial outlook and regulatory progress for its next-generation COVID-19 and H5 pandemic flu vaccine candidates. The community is actively debating the stock's "undervalued" status and the potential for a substantial short squeeze, further bolstered by a broader uptrend in the biotech sector.

BriaCell Therapeutics Corp. is a clinical-stage biotechnology company, which engages in the development of novel immunotherapies to transform cancer care. It currently advancing its Bria-IMT™ targeted immunotherapy in combination with an immune check point inhibitor in a pivotal 1 Phase 3 study in metastatic breast cancer. The company was founded by Charles L. Wiseman and Isaac Benjamin Maresky on July 26, 2006 and is headquartered in West Vancouver, Canada.

BriaCell Therapeutics Corp - Ordinary Shares - New

BriaCell Therapeutics Corp

BriaCell Therapeutics is trending intensely after reporting a sustained, complete resolution of lung metastasis in a metastatic breast cancer patient treated with Bria-OTS. While this clinical data fuels excitement about the therapy's groundbreaking potential, community discussions are sharply divided, with many expressing deep skepticism and anticipating further dilution due to the company's consistent history of public offerings and reverse splits following positive news. This creates a volatile conversation contrasting scientific promise with concerns over long-term shareholder value.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is experiencing heightened attention driven by its upcoming investor presentation at the J.P. Morgan Healthcare Conference, with community discussions buzzing around its significant short interest and the potential for a squeeze. Investors are keenly awaiting announcements regarding new partnerships for its Matrix-M adjuvant technology, particularly in oncology and other vaccine applications, reflecting both strong asset potential and persistent questions about management's ability to capitalize.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Insider Buying: FibroGen (NASDAQ:FGEN) CEO Acquires 2,700 Shares of Stock

FibroGen, Inc (NASDAQ:FGEN - Get Free Report) CEO Thane Wettig bought 2,700 shares of the stock in a transaction on Monday, November 17th. The stock was purchased at an average cost of $9.10 per...

FibroGen (FGEN) Reports Q3 Loss, Lags Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of +59.85% and -34.39%, respectively, for the quarter ended September 2025. Do the numbers hold clues to what lies ahead for the stock?

FibroGen, Inc. (FGEN) on Monday said that a Chinese regulator has approved the sale of its unit FibroGen International (Hong Kong) to AstraZeneca (AZN).FibroGen had announced the sale of its China unit to AstraZeneca for about $160 million in February. The closing of the transaction is now expected in the third quarter of 2025, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://investor.fibrogen.com/news-releases/news-release-details/fibrogen-announces-approval-sale-fibrogen-china-astrazeneca">said</a>. &nbsp;The closing of the transaction remains subject to other contractual closing conditions and deliverables, the biopharmaceutical company added. The firm had previously expected the transaction to close by mid-2025. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/FGEN">FGEN</a> trended in the ‘extremely bullish’ territory over the past 24 hours, while message volume remained at ‘extremely high’ levels.The company said earlier this year that it would repay its term loan facility to investment funds managed by Morgan Stanley Tactical Value following the closing of its transaction in a bid to simplify its capital structure. The transaction is further expected to extend the company’s cash runway into 2027, it added.Upon closing, AstraZeneca will obtain all rights to Roxadustat in China. Roxadustat is currently approved in China, Europe, Japan, and numerous other countries for the treatment of anemia in chronic kidney disease (CKD) patients, irrespective of whether they are on dialysis.The company is currently considering a development plan for Roxadustat in anemia associated with lower-risk myelodysplastic syndrome in the U.S. Myelodysplastic syndromes (MDS) are a group of cancers where bone marrow doesn't produce enough healthy blood cells.FGEN stock is down by 28% this year but up by about 1% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/cryptocurrency/bitcoin-slips-under-116000-while-cardano-solana-lead-altcoin-selloff/chsO7iYRdQw">Bitcoin Slips Under $116,000 While Cardano, Solana Lead Altcoin Selloff</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Mission Bay headquarters and sign for FibroGen, a biotechnology company producing recombinant gelatins for medical devices and pharmaceuticals, San Francisco, California, 2016. (Photo by Smith Collection/Gado/Getty Images).

Fibrogen Gets Regulator’s Green Light To Sell China Unit To AstraZeneca

The company expects the transaction, which was announced in February, to close in the third quarter of 2025.

Equity

The company expects the transaction, which was announced in February, to close in the third quarter of 2025.


FibroGen (FGEN) Reports Q2 Loss, Lags Revenue Estimates

FibroGen (FGEN) delivered earnings and revenue surprises of -50.22% and -53.52%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

FibroGen (FGEN) Reports Q1 Loss, Tops Revenue Estimates

Kyntra Bio, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of novel therapeutics. It focuses on the hypoxia-inducible factor and connective tissue growth factor biology to develop medicines for the treatment of anemia, fibrotic disease, and cancer. The company was founded by Thomas B. Neff on September 29, 1993, and is headquartered in San Francisco, CA.

Kyntra Bio Inc.

Short-Term Volatility, Then Markets Move On

Sustained Risk-Off Until Fed Path Is Clear

Little Impact — Fundamentals Still Rule

Other – Comment Below

Markets pulled back after reports that the DOJ opened a criminal investigation into Federal Reserve Chair Jerome Powell, raising concerns about central bank independence. With rate cuts, inflation, and political pressure all in focus, how do you think this standoff will impact markets in 2026?

How Will the Powell Investigation Impact Markets in 2026?

FGEN
FibroGen Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest FGEN News

FGENFibroGen Inc